Ácido p-cumárico atenua o dano neuromotor e oxidativo no modelo experimental de doença de parkinson em drosophila melanogaster induzido por rotenona

Abstract

Parkinson's disease is one of the most common but still complex neurodegenerative diseases, characterized by a large number of the motor and non-motor alterations that can affect its function to a variable degree. In this study, we investigated the effect of p-coumaric acid on behavioral and neurochemical changes induced by exposure to rotenone in Drosophila melanogaster in a model similar to Parkinson's disease (PD). P-coumaric acid is an important phenolic and antioxidant compound, which may be an alternative in the recovery of neurotoxicity observed in neurodegenerative diseases. To carry out the study, the flies were divided: two groups with a standard diet (control) and two groups with exposure to rotenone (500 μM), after a period of 72 hours a control group and a rotenone group started to receive the diet with p acid. -coumaric (0.3 μM) for another 48 hours. At the end of the 120-hour study (7 days) with 4 groups: Standard diet (control), p-coumaric acid (0.3 μM), rotenone (500 μM), and rotenone (500 μM) plus p-coumaric acid (0. 3 μM). Exposure to p-coumaric acid reduced rotenone-induced mortality, in addition, oxidative stress indicators were normalized reactive species (RS), Thiobarbituric Acid Reactive Species (TBARS), superoxide dismutase (SOD), catalase activity (CAT), glutathione-S-transferase (GST) and non-protein thiol (NPSH) preventing oxidative damage, and there the was the restoration of dopamine levels. The results demonstrate that p-coumaric acid effectively reduced the damage caused by the Parkinson's disease model. P-coumaric acid is a non-flavonoid phenolic compound that has safety and efficacy that has been widely explored in food science due to its excellent antioxidant and anti-inflammatory properties, in addition to having low oral toxicity, and properties still little explored in drug products. Complementary studies are needed to elucidate p-coumaric acid as a possible therapeutic target for new drugs in the treatment of Parkinson's disease.